Experts pointed out the lack of clarity in professional standards and regulations when it comes to dealing with genetic variation in patient care.
A high-profile, independent committee is considering the liability issues impacting labs as genetic testing increasingly becomes integrated into patient care.
A hedge fund that invested in Theranos files a lawsuit, the Wall Street Journal reports.
Qiagen plans to appeal the decision to block the sale of its GeneReader NGS system and is also working on an upgrade to replace the portion under dispute.
Under the terms of the settlement, Illumina and co-plaintiffs can request up to five audits of Oxford Nanopore's products.
The email, which claimed the Broad Institute did not deserve key CRISPR patents, is one of several attention-grabbing items in newly released documents.
It is now up to Margaret Seymour, a senior judge in US District Court in the District of South Carolina, whether Williams' case should be dismissed or decided by a jury.
Law.com predicts that genomic and genetic testing will become common in toxic tort cases.
The affidavit from pediatric neurologist Max Wiznitzer is part of a plan by Amy Williams' lawyers to convince the court to take up their client's case.
Columbia University settles a civil fraud lawsuit that said it improperly used its on-campus indirect cost rate when seeking reimbursement for more than 400 grants.
In PLOS this week: role for Notch signaling in congenital heart disease, sciatica risk variants, and more.
Researchers in China have used the CRISPR/Cas9 genome editing approach to alter the length of hair fibers in cashmere goats.
According to ScienceInsider, the Scripps Research Institute and the California Institute for Biomedical Research are merging.
National Cancer Institute researchers didn't report severe adverse events to Food and Drug Administration in a timely manner, the Wall Street Journal reports.